Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

PHASE3CompletedINTERVENTIONAL
Enrollment

467

Participants

Timeline

Start Date

May 22, 2017

Primary Completion Date

July 9, 2019

Study Completion Date

January 27, 2020

Conditions
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Interventions
DRUG

Evolocumab

Dose of subcutaneous evolocumab QM

DRUG

Placebo

Dose of matching placebo QM

Trial Locations (78)

1000

Research Site, Brussels

1011

Research Site, Lausanne

1211

Research Site, Geneva

2000

Research Site, Antwerp

2010

Research Site, Darlinghurst

Research Site, East Sydney

Research Site, Sydney

2092

Research Site, Westdene

3004

Research Site, Melbourne

3181

Research Site, Prahran

4006

Research Site, Fortitude Valley

6900

Research Site, Lugano

8091

Research Site, Zurich

9000

Research Site, Ghent

9301

Research Site, Bloemfontein

10029

Research Site, New York

10467

Research Site, The Bronx

10676

Research Site, Athens

11527

Research Site, Athens

12208

Research Site, Albany

12462

Research Site, Athens

16121

Research Site, Athens

16132

Research Site, Genova

20005

Research Site, Washington D.C.

20007

Research Site, Washington D.C.

20037

Research Site, Washington D.C.

20157

Research Site, Milan

22042

Research Site, Falls Church

28040

Research Site, Madrid

28046

Research Site, Madrid

30912

Research Site, Augusta

32960

Research Site, Vero Beach

33075

Research Site, Bordeaux

33136

Research Site, Miami

33602

Research Site, Tampa

34295

Research Site, Montpellier

40138

Research Site, Bologna

41100

Research Site, Modena

44093

Research Site, Nantes

45267

Research Site, Cincinnati

48072

Research Site, Berkley

48075

Research Site, Southfield

48202

Research Site, Detroit

54636

Research Site, Thessaloniki

55415

Research Site, Minneapolis

56124

Research Site, Pisa

63110

Research Site, St Louis

69317

Research Site, Lyon

75475

Research Site, Paris

75571

Research Site, Paris

75651

Research Site, Paris

90035

Research Site, Los Angeles

300310

Research Site, Timișoara

500174

Research Site, Brasov

900708

Research Site, Constanța

06102

Research Site, Hartford

08103

Research Site, Camden

04121-000

Research Site, São Paulo

21040-900

Research Site, Rio de Janeiro

05403-000

Research Site, São Paulo

T2R 0X7

Research Site, Calgary

V6Z 1Y6

Research Site, Vancouver

L8S 1A4

Research Site, Hamilton

H4A 3T2

Research Site, Montreal

G1V 4G2

Research Site, Québec

00149

Research Site, Roma

01-201

Research Site, Warsaw

2801-951

Research Site, Almada

3814-501

Research Site, Aveiro

3000-075

Research Site, Coimbra

4200-319

Research Site, Porto

021105

Research Site, Bucharest

0122

Research Site, Pretoria

08035

Research Site, Barcelona

08036

Research Site, Barcelona

SE1 9RT

Research Site, London

SW10 9NH

Research Site, London

W2 1NY

Research Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY